20 results on '"Silvia Rosellini"'
Search Results
2. Supplementary Figure 2 from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- Author
-
Jean-Charles Soria, Fabrice André, Alexander Eggermont, Gilles Vassal, Eric Angevin, Eric Deutsch, Vincent Ribrag, Catherine Richon, Vladimir Lazar, Jean-Yves Scoazec, Philippe Vielh, Frederic Deschamps, Thierry De Baere, Bastien Job, Nathalie Auger, Ingrid Breuskin, Caroline Even, Yohann Loriot, Sophie Postel-Vinay, Andrea Varga, Anas Gazzah, Rastislav Bahleda, Maud Ngo-Camus, Samy Ammari, Silvia Rosellini, Ecaterina Ileana, Loic Verlingue, Antoine Hollebecque, Ludovic Lacroix, Marie-Cécile Le Deley, Charles Ferté, Stefan Michiels, and Christophe Massard more...
- Abstract
Individual PFS2 vs PFS1 profile plot. Each patient has been aligned at time 0 of PFS2 and sorted by the sum of PFS1 and PFS2.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
3. Supplementary Figure 1 from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- Author
-
Jean-Charles Soria, Fabrice André, Alexander Eggermont, Gilles Vassal, Eric Angevin, Eric Deutsch, Vincent Ribrag, Catherine Richon, Vladimir Lazar, Jean-Yves Scoazec, Philippe Vielh, Frederic Deschamps, Thierry De Baere, Bastien Job, Nathalie Auger, Ingrid Breuskin, Caroline Even, Yohann Loriot, Sophie Postel-Vinay, Andrea Varga, Anas Gazzah, Rastislav Bahleda, Maud Ngo-Camus, Samy Ammari, Silvia Rosellini, Ecaterina Ileana, Loic Verlingue, Antoine Hollebecque, Ludovic Lacroix, Marie-Cécile Le Deley, Charles Ferté, Stefan Michiels, and Christophe Massard more...
- Abstract
Genes that contain molecular alterations matched with therapies according to tumor type.
- Published
- 2023
- Full Text
- View/download PDF
4. Supplementary Figure Legends from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- Author
-
Jean-Charles Soria, Fabrice André, Alexander Eggermont, Gilles Vassal, Eric Angevin, Eric Deutsch, Vincent Ribrag, Catherine Richon, Vladimir Lazar, Jean-Yves Scoazec, Philippe Vielh, Frederic Deschamps, Thierry De Baere, Bastien Job, Nathalie Auger, Ingrid Breuskin, Caroline Even, Yohann Loriot, Sophie Postel-Vinay, Andrea Varga, Anas Gazzah, Rastislav Bahleda, Maud Ngo-Camus, Samy Ammari, Silvia Rosellini, Ecaterina Ileana, Loic Verlingue, Antoine Hollebecque, Ludovic Lacroix, Marie-Cécile Le Deley, Charles Ferté, Stefan Michiels, and Christophe Massard more...
- Abstract
Supplementary Figure Legends
- Published
- 2023
- Full Text
- View/download PDF
5. Supplementary Figure 1 from Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
- Author
-
Ludovic Lacroix, Jean-Charles Soria, Fabrice André, Alexander Eggermont, Gilles Vassal, Jean-Yves Scoazec, Philippe Vielh, Thierry De Baere, Maud Ngo-Camus, Sophie Postel-Vinay, Amélie Boichard, Charles Ferté, Antoine Hollebecque, Christophe Massard, Marc Deloger, Nathalie Droin, Noémie Pata-Merci, Marion Pedrero, Celine Lefebvre, Alfredo Romero, Silvia Rosellini, Nelly Motté, Marie-Cécile Le Deley, Ecaterina Ileana, and Cécile Jovelet more...
- Abstract
Sensitivity Prediction Score ROC Curve of the logistic regression model.
- Published
- 2023
- Full Text
- View/download PDF
6. Supplementary Table 1 from Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
- Author
-
Ludovic Lacroix, Jean-Charles Soria, Fabrice André, Alexander Eggermont, Gilles Vassal, Jean-Yves Scoazec, Philippe Vielh, Thierry De Baere, Maud Ngo-Camus, Sophie Postel-Vinay, Amélie Boichard, Charles Ferté, Antoine Hollebecque, Christophe Massard, Marc Deloger, Nathalie Droin, Noémie Pata-Merci, Marion Pedrero, Celine Lefebvre, Alfredo Romero, Silvia Rosellini, Nelly Motté, Marie-Cécile Le Deley, Ecaterina Ileana, and Cécile Jovelet more...
- Abstract
mutations' allele frequencies in tDNA and cfDNA
- Published
- 2023
- Full Text
- View/download PDF
7. Data from Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
- Author
-
Ludovic Lacroix, Jean-Charles Soria, Fabrice André, Alexander Eggermont, Gilles Vassal, Jean-Yves Scoazec, Philippe Vielh, Thierry De Baere, Maud Ngo-Camus, Sophie Postel-Vinay, Amélie Boichard, Charles Ferté, Antoine Hollebecque, Christophe Massard, Marc Deloger, Nathalie Droin, Noémie Pata-Merci, Marion Pedrero, Celine Lefebvre, Alfredo Romero, Silvia Rosellini, Nelly Motté, Marie-Cécile Le Deley, Ecaterina Ileana, and Cécile Jovelet more...
- Abstract
Purpose: Liquid biopsies based on circulating cell-free DNA (cfDNA) analysis are described as surrogate samples for molecular analysis. We evaluated the concordance between tumor DNA (tDNA) and cfDNA analysis on a large cohort of patients with advanced or metastatic solid tumor, eligible for phase I trial and with good performance status, enrolled in MOSCATO 01 trial (clinical trial NCT01566019).Experimental Design: Blood samples were collected at inclusion and cfDNA was extracted from plasma for 334 patients. Hotspot mutations were screened using next-generation sequencing for 50 cancer genes.Results: Among the 283 patients with tDNA–cfDNA pairs, 121 had mutation in both, 99 in tumor only, 5 in cfDNA only, and for 58 patients no mutation was detected, leading to a 55.0% estimated sensitivity [95% confidence interval (CI), 48.4%–61.6%] at the patient level. Among the 220 patients with mutations in tDNA, the sensitivity of cfDNA analysis was significantly linked to the number of metastatic sites, albumin level, tumor type, and number of lines of treatment. A sensitivity prediction score could be derived from clinical parameters. Sensitivity is 83% in patients with a high score (≥8). In addition, we analyzed cfDNA for 51 patients without available tissue sample. Mutations were detected for 22 patients, including 19 oncogenic variants and 8 actionable mutations.Conclusions: Detection of somatic mutations in cfDNA is feasible for prescreening phase I candidates with a satisfactory specificity; overall sensitivity can be improved by a sensitivity score allowing to select patients for whom cfDNA constitutes a reliable noninvasive surrogate to screen mutations. Clin Cancer Res; 22(12); 2960–8. ©2016 AACR. more...
- Published
- 2023
- Full Text
- View/download PDF
8. Experimental study of a reverse osmosis pilot plant for reuse of refinery wastewater
- Author
-
Alice Lavarone, Giovanni Scarsi, Ezio Saturno, Silvia Rosellini, Paola Costamagna, and Valter Mantelli
- Subjects
Waste management ,Renewable Energy, Sustainability and the Environment ,General Chemical Engineering ,Organic Chemistry ,refinery ,Reuse ,reverse osmosis ,wastewater treatment ,water reuse ,Pollution ,Refinery ,Inorganic Chemistry ,Fuel Technology ,Refinery wastewater ,Pilot plant ,Environmental science ,Sewage treatment ,Reverse osmosis ,Waste Management and Disposal ,Biotechnology - Published
- 2021
9. Multi-scale model of a top-fired steam methane reforming reactor and validation with industrial experimental data
- Author
-
Paola Costamagna, Silvia Rosellini, Alberto Servida, Valeria Tacchino, and Valter Mantelli
- Subjects
Mesoscopic physics ,Finite element method (FEM) ,Scale (ratio) ,General Chemical Engineering ,Nuclear engineering ,Modeling ,Furnace ,Steam methane reforming (SMR) ,General Chemistry ,Industrial and Manufacturing Engineering ,Microscopic scale ,Symmetry (physics) ,Finite element method ,Momentum ,Steam reforming ,Environmental Chemistry ,Environmental science ,Physics::Chemical Physics ,Scale model ,Multi-scale ,Hydrogen - Abstract
A multi-scale model is presented for a steam methane reforming reactor. The reactor is a typical top-fired, packed-bed multi-tubular reactor. The model embeds, at the microscopic scale, a 1-dimensional simulation of mass transport and reaction inside the catalyst particles. At the intermediate (mesoscopic) scale, the tubular reactor model is based on local mass, energy, and momentum balances, coupled to appropriate steam methane reforming reaction kinetics; the equations are written and solved in 2-dimensional cylindrical symmetry. At the macroscopic level, the tube simulation is then coupled to the furnace simulation. For the latter, a 1-dimensional model is proposed, based on local mass and energy balances, coupled to linear combustion kinetics. Overall, the model contains only one adjustable parameter i.e., Lf, the length of the flame in the furnace. The model equations are integrated through a finite element method. The predictive capability of the model is assessed through validation against previous literature results, as well as three sets of experimental data obtained from a full-scale industrial SMR reactor, operating from middle to high capacity. The model makes it possible to account for the effects of the catalyst features, on the one hand, and the operating conditions of the furnace, on the other. The model provides a detailed study of the phenomena occurring inside the steam methane reforming reactor, with an acceptable computational burden and time. This lays the foundations for in-depth fault detection and identification studies and online deployment of the model for control purposes. more...
- Published
- 2022
- Full Text
- View/download PDF
10. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients
- Author
-
Eric Rosenthal, Silvia Rosellini, Linda Wittkop, Dominique Salmon-Ceron, Isabelle Poizot-Martin, Laure Esterle, François Raffi, Bruno Spire, Maria Patrizia Carrieri, David Zucman, Fabienne Marcellin, Camelia Protopopescu, and François Dabis more...
- Subjects
Adult ,Male ,medicine.medical_specialty ,Population ,HIV Infections ,Coffee ,03 medical and health sciences ,0302 clinical medicine ,Cause of Death ,Internal medicine ,Humans ,Medicine ,Prospective Studies ,030212 general & internal medicine ,education ,Prospective cohort study ,Aged ,Proportional Hazards Models ,Cause of death ,education.field_of_study ,Hepatology ,Coinfection ,business.industry ,Mortality rate ,Hazard ratio ,Hepatitis C ,Middle Aged ,medicine.disease ,Surgery ,Cohort ,Female ,030211 gastroenterology & hepatology ,business - Abstract
Background & Aims Coffee has anti-inflammatory and hepato-protective properties. In the general population, drinking ≥3cups of coffee/day has been associated with a 14% reduction in the risk of all-cause mortality. The aim of this study was to investigate the relationship between coffee consumption and the risk of all-cause mortality in patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Methods ANRS CO13 HEPAVIH is an ongoing French nationwide prospective cohort of patients co-infected with HIV-HCV collecting both medical and psychosocial/behavioural data (annual self-administered questionnaires). We used a Cox proportional hazards model to estimate the effect of elevated coffee consumption (≥3cups/day) at baseline on all-cause mortality during the cohort's five-year follow-up. Results Over a median [interquartile range] follow-up of 5.0 [3.9–5.9] years, 77 deaths occurred among 1,028 eligible patients (mortality rate 1.64/100 person-years; 95% confidence interval [CI] 1.31–2.05). Leading causes of death were HCV-related diseases (n=33, 43%), cancers unrelated to AIDS/HCV (n=9, 12%), and AIDS (n=8, 10%). At the first available visit, 26.6% of patients reported elevated coffee consumption. Elevated coffee consumption at baseline was associated with a 50% reduced risk of all-cause mortality (hazard ratio 0.5; CI 0.3–0.9; p =0.032), after adjustment for gender and psychosocial, behavioral and clinical time-varying factors. Conclusions Drinking three or more cups of coffee per day halves all-cause mortality risk in patients co-infected with HIV-HCV. The benefits of coffee extracts and supplementing dietary intake with other anti-inflammatory compounds need to be evaluated in this population. Lay summary Coffee has anti-inflammatory and hepato-protective properties but its effect on mortality risk has never been investigated in patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). This study shows that elevated coffee consumption (≥3cups/day) halves all-cause mortality risk in patients co-infected with HIV-HCV. The benefits of coffee extracts and supplementing dietary intake with other anti-inflammatory compounds need to be evaluated in this population. more...
- Published
- 2017
- Full Text
- View/download PDF
11. Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status
- Author
-
Dan Ou, Pierre Blanchard, Silvia Rosellini, Antonin Levy, France Nguyen, Ralph T.H. Leijenaar, Ingrid Garberis, Philippe Gorphe, François Bidault, Charles Ferté, Charlotte Robert, Odile Casiraghi, Jean-Yves Scoazec, Philippe Lambin, Stephane Temam, Eric Deutsch, Yungan Tao, Radiotherapie, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy more...
- Subjects
Male ,Oncology ,OROPHARYNGEAL CANCER ,BIOMARKER ,Cancer Research ,Multivariate analysis ,medicine.medical_treatment ,Alphapapillomavirus ,Bioradiotherapy ,030218 nuclear medicine & medical imaging ,0302 clinical medicine ,Locally advanced head and neck cancer ,HETEROGENEITY ,Cetuximab ,Chemoradiotherapy ,Middle Aged ,CHEMOTHERAPY ,Prognosis ,Primary tumor ,CETUXIMAB ,3. Good health ,SQUAMOUS-CELL CARCINOMAS ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,SURVIVAL ,Biomarker (medicine) ,Female ,Oral Surgery ,medicine.drug ,RADIOTHERAPY ,medicine.medical_specialty ,HPV ,03 medical and health sciences ,CISPLATIN ,TEXTURE ANALYSIS ,Internal medicine ,medicine ,Humans ,Aged ,Retrospective Studies ,Radiomics ,Receiver operating characteristic ,Squamous Cell Carcinoma of Head and Neck ,Proportional hazards model ,business.industry ,medicine.disease ,Survival Analysis ,Radiation therapy ,Tomography, X-Ray Computed ,business - Abstract
Objectives: To explore prognostic and predictive value of radiomics in patients with locally advanced head and neck squamous cell carcinomas (LAHNSCC) treated with concurrent chemoradiotherapy (CRT) or bioradiotherapy (BRT).Materials and Methods: Data of 120 patients (CRT vs. BRT matched 2: 1) were retrospectively analyzed. A total of 544 radiomics features of the primary tumor were extracted from radiotherapy planning computed tomography scans. Cox proportional hazards models were used to examine the association between survival and radiomics features with false discovery rate correction. The discriminatory performance was evaluated using receiver operating characteristic curve analysis.Results: Multivariate analysis showed a 24-feature based signature significantly predicted for OS (HR = 0.3, P = 0.02) and progression-free survival (PFS) (HR = 0.3, P = 0.01). Combining the radiomics signature with p16 status showed a significant improvement of prognostic performance compared with p16 (AUC = 0.78 vs. AUC = 0.64 at 5 years, P = 0.01) or radiomics signature (AUC = 0.78 vs. AUC = 0.67, P = 0.01) alone. When patients were stratified according to this combination, OS and PFS were significantly different according to the 4 sub-types (p16+ with low/high signature score; p16-with low/high signature score) (P Conclusion: Our analysis suggests an added value of radiomics features as prognostic and predictive biomarker in HNSCC treated with CRT/BRT. Moreover, the radiomics signature provided additional information to HPV/p16 status to further stratify patients. External validation of such findings is mandatory given the risk of overfitting. (C) 2017 Elsevier Ltd. All rights reserved. more...
- Published
- 2017
12. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- Author
-
Frederic Deschamps, Christophe Massard, Yohann Loriot, Antoine Hollebecque, Loic Verlingue, Sophie Postel-Vinay, Nathalie Auger, Ingrid Breuskin, Fabrice Andre, Maud Ngo-Camus, Eric Angevin, Rastislav Bahleda, Ludovic Lacroix, Jean-Charles Soria, Caroline Even, Jean-Yves Scoazec, Charles Ferté, Anas Gazzah, Bastien Job, Catherine Richon, Gilles Vassal, Ecaterina Ileana, Marie-Cécile Le Deley, Philippe Vielh, Andrea Varga, Vladimir Lazar, Silvia Rosellini, Samy Ammari, Alexander M.M. Eggermont, Stefan Michiels, Vincent Ribrag, Thierry de Baere, and Eric Deutsch more...
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,MEDLINE ,Bioinformatics ,Disease-Free Survival ,Article ,Targeted therapy ,law.invention ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Neoplasms ,Internal medicine ,Biopsy ,medicine ,Humans ,Molecular Targeted Therapy ,Young adult ,Aged ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,High-Throughput Nucleotide Sequencing ,Cancer ,Genomics ,Middle Aged ,medicine.disease ,Clinical trial ,Treatment Outcome ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,business ,Comparative genomic hybridization - Abstract
High-throughput genomic analyses may improve outcomes in patients with advanced cancers. MOSCATO 01 is a prospective clinical trial evaluating the clinical benefit of this approach. Nucleic acids were extracted from fresh-frozen tumor biopsies and analyzed by array comparative genomic hybridization, next-generation sequencing, and RNA sequencing. The primary objective was to evaluate clinical benefit as measured by the percentage of patients presenting progression-free survival (PFS) on matched therapy (PFS2) 1.3-fold longer than the PFS on prior therapy (PFS1). A total of 1,035 adult patients were included, and a biopsy was performed in 948. An actionable molecular alteration was identified in 411 of 843 patients with a molecular portrait. A total of 199 patients were treated with a targeted therapy matched to a genomic alteration. The PFS2/PFS1 ratio was >1.3 in 33% of the patients (63/193). Objective responses were observed in 22 of 194 patients (11%; 95% CI, 7%–17%), and median overall survival was 11.9 months (95% CI, 9.5–14.3 months). Significance: This study suggests that high-throughput genomics could improve outcomes in a subset of patients with hard-to-treat cancers. Although these results are encouraging, only 7% of the successfully screened patients benefited from this approach. Randomized trials are needed to validate this hypothesis and to quantify the magnitude of benefit. Expanding drug access could increase the percentage of patients who benefit. Cancer Discov; 7(6); 586–95. ©2017 AACR. See related commentary by Schram and Hyman, p. 552. This article is highlighted in the In This Issue feature, p. 539 more...
- Published
- 2017
- Full Text
- View/download PDF
13. Outcomes of multimodal management for sinonasal squamous cell carcinoma
- Author
-
Antoine Moya Plana, Pierre Blanchard, Frédéric Kolb, Arnaud Paré, François Bidault, Stéphane Temam, A. Auperin, Odile Casiraghi, Philippe Page, Philippe Gorphe, Silvia Rosellini, and François Janot
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Basal cell ,030223 otorhinolaryngology ,Pathological ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,business.industry ,Soft tissue ,Cancer ,Multimodal therapy ,Middle Aged ,medicine.disease ,Prognosis ,Combined Modality Therapy ,Treatment Outcome ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Locally advanced disease ,Carcinoma, Squamous Cell ,Surgery ,Female ,Oral Surgery ,business ,Wide resection ,Paranasal Sinus Neoplasms - Abstract
Background Poor prognosis of sinonasal cancers (SNC) is usually due to the non-specific symptoms leading to late diagnosis with locally advanced disease . However, previous prognostic studies were often based on heterogeneous cohorts because of the scarcity of SNC. With squamous cell carcinoma being the main histological subgroup, the study aimed to perform a prognostic analysis on sinonasal squamous cell carcinoma (SNSCC) particularly, and to evaluate the oncological results of a multimodal therapy. Methods A retrospective review of 68 cases involving SNSCC treatment between 1998 and 2012 at Gustave Roussy Cancer Campus was performed. Clinical, pathological, and treatment characteristics were evaluated as prognostic markers for oncological outcomes. Results The 5-year overall survival (OS) and progression-free survival (PFS) rates were 58.1% and 52.6% respectively. Tumor downsizing under neoadjuvant chemotherapy (NACT) was observed in 82.5% of cases. The main pattern of recurrence was local with a 2- and 5-year rate of 37.3%. Decreased OS, PFS and local control were associated with involvement of the orbit, the soft tissue, and the suprastructure ( p Conclusion Prognosis of surgically treated SNSCC remains poor. Multimodal treatment combining NACT followed by wide resection requiring complex reconstruction and adjuvant radiation therapy seems to provide promising results. more...
- Published
- 2017
14. Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01)
- Author
-
Cécile Charpy, Valerie Koubi-Pick, Behnoush Abedi-Ardekani, Désirée Deandreis, Ludovic Lacroix, Antoine Hollebecque, Antoine Hakime, Gilles Vassal, Siham Gouissem, Maud Ngo-Camus, Silvia Rosellini, Philippe Vielh, Ecaterina Ileana, Marie-Cécile Le Deley, Charles Ferté, Vania Tacher, Fabrice Andre, Thierry de Baere, Aljosa Celebic, Dorota Gajda, Frederic Deschamps, Jean-Charles Soria, and Christophe Massard more...
- Subjects
Target lesion ,Adult ,Image-Guided Biopsy ,Male ,Image-guided tumour biopsies ,Molecular triage ,Cancer Research ,Oncology ,medicine.medical_specialty ,030218 nuclear medicine & medical imaging ,Lesion ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Interquartile range ,Neoplasms ,Biopsy ,medicine ,Humans ,Prospective Studies ,Neoplasm Metastasis ,Aged ,Aged, 80 and over ,Lung ,medicine.diagnostic_test ,business.industry ,Cancer ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Pneumothorax ,030220 oncology & carcinogenesis ,Female ,Radiology ,medicine.symptom ,Triage ,business ,Complication - Abstract
MOSCATO-01 is a molecular triage trial based on on-purpose tumour biopsies to perform molecular portraits. We aimed at identifying factors associated with high tumour cellularity.Tumour cellularity (percentage of tumour cells in samples defined at pathology) was evaluated according to patient characteristics, target lesion characteristics, operators' experience and biopsy approach.Among 460 patients enrolled between November, 2011 and March, 2014, 334 patients (73%) had an image-guided needle biopsy of the primary tumour (N = 38) or a metastatic lesion (N = 296). Biopsies were performed on liver (N = 127), lung (N = 72), lymph nodes (N = 71), bone (N = 11), or another tumour site (N = 53). Eighteen patients (5%) experienced a complication: pneumothorax in 10 patients treated medically, and haemorrhage in 8, requiring embolisation in 3 cases. Median tumour cellularity was 50% (interquartile range, 30-70%). The molecular analysis was successful in 291/334 cases (87%). On-going chemotherapy, tumour origin (primary versus metastatic), lesion size, tumour growth rate, presence of necrosis on imaging, standardised uptake value, and needle size were not statistically associated with cellularity. Compared to liver or lung biopsies, cellularity was significantly lower in bone and higher in other sites (P 0.0001). Cellularity significantly increased with the number of collected samples (P 0.0001) and was higher in contrast-enhanced ultrasound-guided biopsies (P 0.02). In paired samples, cellularity in central samples was lower than in peripheral samples in 85, equal in 68 and higher in 89 of the cases.Image-guided biopsy is feasible and safe in cancer patients for molecular screening. Imaging modality, multiple sampling of the lesion, and the organ chosen for biopsy were associated with higher tumour cellularity. more...
- Published
- 2016
15. Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study
- Author
-
Virginia, Bluthgen Maria, primary, Laura, Faivre, additional, Silvia, Rosellini, additional, Roberto, Ferrara, additional, Francesco, Facchinetti, additional, Eva, Haspinger, additional, Charles, Ferte, additional, Samy, Ammari, additional, Stefan, Michiels, additional, Jean-Charles, Soria, additional, Caroline, Caramella, additional, and Benjamin, Besse, additional more...
- Published
- 2017
- Full Text
- View/download PDF
16. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
- Author
-
Charles Ferté, Sophie Postel-Vinay, Antoine Hollebecque, Celine Lefebvre, Maud Ngo-Camus, Amelie Boichard, Thierry de Baere, Marie-Cécile Le Deley, Alfredo Romero, Nelly Motté, Cécile Jovelet, Marc Deloger, Jean-Charles Soria, Marion Pedrero, Silvia Rosellini, Ecaterina Ileana, Ludovic Lacroix, Jean-Yves Scoazec, Alexander M.M. Eggermont, Nathalie Droin, Gilles Vassal, Fabrice Andre, Philippe Vielh, Christophe Massard, and Noémie Pata-Merci more...
- Subjects
0301 basic medicine ,Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Concordance ,DNA Mutational Analysis ,Bioinformatics ,medicine.disease_cause ,DNA sequencing ,Circulating Tumor DNA ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,Neoplasms ,medicine ,Biomarkers, Tumor ,Humans ,Molecular Targeted Therapy ,Prospective Studies ,Prospective cohort study ,Gene ,Aged ,Mutation ,Performance status ,Clinical Trials, Phase I as Topic ,business.industry ,Patient Selection ,High-Throughput Nucleotide Sequencing ,DNA, Neoplasm ,Middle Aged ,Clinical trial ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,business - Abstract
Purpose: Liquid biopsies based on circulating cell-free DNA (cfDNA) analysis are described as surrogate samples for molecular analysis. We evaluated the concordance between tumor DNA (tDNA) and cfDNA analysis on a large cohort of patients with advanced or metastatic solid tumor, eligible for phase I trial and with good performance status, enrolled in MOSCATO 01 trial (clinical trial NCT01566019). Experimental Design: Blood samples were collected at inclusion and cfDNA was extracted from plasma for 334 patients. Hotspot mutations were screened using next-generation sequencing for 50 cancer genes. Results: Among the 283 patients with tDNA–cfDNA pairs, 121 had mutation in both, 99 in tumor only, 5 in cfDNA only, and for 58 patients no mutation was detected, leading to a 55.0% estimated sensitivity [95% confidence interval (CI), 48.4%–61.6%] at the patient level. Among the 220 patients with mutations in tDNA, the sensitivity of cfDNA analysis was significantly linked to the number of metastatic sites, albumin level, tumor type, and number of lines of treatment. A sensitivity prediction score could be derived from clinical parameters. Sensitivity is 83% in patients with a high score (≥8). In addition, we analyzed cfDNA for 51 patients without available tissue sample. Mutations were detected for 22 patients, including 19 oncogenic variants and 8 actionable mutations. Conclusions: Detection of somatic mutations in cfDNA is feasible for prescreening phase I candidates with a satisfactory specificity; overall sensitivity can be improved by a sensitivity score allowing to select patients for whom cfDNA constitutes a reliable noninvasive surrogate to screen mutations. Clin Cancer Res; 22(12); 2960–8. ©2016 AACR. more...
- Published
- 2015
17. 3133 Prognostic value of texture analysis and correlation with molecular profile in EGFR mutated/ALK rearranged advanced non-small cell lung cancer (NSCLC)
- Author
-
Charles Ferté, Maria Bluthgen, Stefan Michiels, Caroline Caramella, E. Haspinger, Benjamin Besse, Charlotte Leduc, Francesco Facchinetti, Jeannette Soria, and Silvia Rosellini
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,non-small cell lung cancer (NSCLC) ,medicine.disease ,Correlation ,Internal medicine ,medicine ,Molecular Profile ,Texture (crystalline) ,business ,Value (mathematics) - Published
- 2015
- Full Text
- View/download PDF
18. 3127 Prognostic value of texture analysis in advanced non-small cell lung cancer (NSCLC)
- Author
-
Jeannette Soria, Laura Faivre, Benjamin Besse, Stefan Michiels, Silvia Rosellini, Francesco Facchinetti, Maria Bluthgen, E. Haspinger, Samy Ammari, Charles Ferté, and Caroline Caramella
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,non-small cell lung cancer (NSCLC) ,medicine.disease ,business ,Texture (geology) ,Value (mathematics) - Published
- 2015
- Full Text
- View/download PDF
19. 467 Radiomics to identify HER2 amplification or mutation in metastatic patients with solid tumors prospectively enrolled in MOSCATO-01
- Author
-
Maria Bluthgen, Silvia Rosellini, Ludovic Lacroix, Laurent Dercle, Benjamin Besse, Caroline Caramella, Stefan Michiels, Samy Ammari, Christophe Massard, Charles Ferté, E. Haspinger, Frederic Deschamps, T. de Baere, and Jeannette Soria more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Radiomics ,business.industry ,Internal medicine ,Mutation (genetic algorithm) ,medicine ,HER2 Amplification ,business - Published
- 2015
- Full Text
- View/download PDF
20. Abstract 2401: Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial
- Author
-
Anas Gazzah, Ecaterina Ileana, Gilles Vassal, Sophie Postel-Vinay, Charles Ferté, Silvia Rosellini, Philippe Vielh, Mélanie Laporte, Amelie Boichard, Cécile Jovelet, Rastilav Bahleda, Catherine Richon, Andrea Varga, Antoine Hollebecque, Siham Gouissem, Yohann Loriot, Maud Ngo-Camus, Fabrice Andre, Nelly Motté, Ludovic Lacroix, Thierry de Baere, Jean-Charles Soria, Marie-Cécile Le Deley, Christophe Massard, and Alexander M.M. Eggermont more...
- Subjects
Oncology ,Cancer Research ,Pathology ,medicine.medical_specialty ,Mutation ,medicine.diagnostic_test ,business.industry ,Cancer ,medicine.disease ,medicine.disease_cause ,DNA sequencing ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Biopsy ,medicine ,KRAS ,Prospective cohort study ,business ,Gene ,DNA - Abstract
Background Precision-medicine initiatives are driven by the molecular analysis of tumor samples (fresh or FFPE material). Such an approach is limited by the availability of the tumor material and the challenges related to on-purpose tumor biopsies. A very appealing alternative to advance precision-medicine initiatives is the development of liquid biopsies using cfDNA. Methods We investigated the use of NGS on tumor biopsy and plasma, and evaluated the consistency between the tissue biopsy (tDNA) and cfDNA analysis on a prospective cohort of patients with metastatic or locally advanced solid tumors enrolled in the MOSCATO 01 trial (NCT01566019). Blood samples were collected at inclusion before tumor biopsy and cfDNA was extracted from 500μl plasma. Hot-spot mutations from 50 genes were screened with Ampliseq CHP2 panel (IonTorrent, Life Technologies, Dramstadt). Only variants reported by the Torrent Suite Variant Caller v4.2 were retained for the analysis. Paired results in tumor and plasma were described using Cohen's Kappa agreement coefficient (κ). Results From November 2011 to May 2014, among the 516 patients enrolled in the MOSCATO 01 trial, 190 patients (37%) were analyzed for tDNA and cfDNA. In addition, cfDNA was evaluated in 43 patients for whom no tumor analysis was performed because of low cellularity (< 10% of tumor cells). Patient characteristics were as follows: median age at biopsy: 57 years (range, 18-78); main tumor types: lung (19%), ENT (14%), colorectal (10%), breast (10%); median of 3 previous lines of treatment. Overall, 325 mutations were identified in the tDNA of 184 patients: 146 mutations were identified both in tumor and plasma and 179 in tumor, but not in plasma. 15 mutations were only found in cfDNA, thereby providing additional information. The κ.was 59% (95%CI, 0.54-0.64). The sensibility of using NGS for 50 targeted hot-spot genes analysis in cfDNA compared to tDNA was 44.9% and the specificity was 99.8%, with a positive predictive value of 90.7% and negative predictive value of 98.1%. The ten most frequent pathogenic mutations found in the tDNA or cfDNA (>5 cases each) included KRAS (33 cases), PIK3CA (22 cases) and TP53 genes (22 cases). When considering only these ten most frequent mutations, 77 mutations were identified in 71 patients: 39 in tumor and plasma, 36 in tumor, but not in plasma and 2 mutations only in plasma, with a κ of 66% (95%CI, 56-76%). The p.H1047R PIK3CA mutation, was found only in tumor (5 cases); for the other nine mutations, the κ coefficient varied from 56% to 89%, with a median of 75%. The cfDNA analysis of the 43 patients without tDNA analysis revealed at least one mutation in 24 patients (56%), including 11 pathogenic variants of therapeutic interest. Conclusion The analysis of cfDNA using NGS represents an attractive and noninvasive alternative to tumor biopsies, and can be used as a surrogate method to screen for mutations. Further prospective validation is warranted. Citation Format: Ecaterina Ileana, Cécile Jovelet, Marie-Cécile Le Deley, Christophe Massard, Nelly Motté, Antoine Hollebecque, Amélie Boichard, Charles Ferté, Sophie Postel-Vinay, Silvia Rosellini, Maud Ngo-Camus, Thierry De Baere, Philippe Vielh, Catherine Richon, Mélanie Laporte, Siham Gouissem, Yohann Loriot, Rastilav Bahleda, Anas Gazzah, Andrea Varga, Gilles Vassal, Alexander Eggermont, Fabrice André, Jean-Charles Soria, Ludovic Lacroix. Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2401. doi:10.1158/1538-7445.AM2015-2401 more...
- Published
- 2015
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.